| 000 | 01102 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250517020128.0 | ||
| 264 | 0 | _c20160120 | |
| 008 | 201601s 0 0 eng d | ||
| 022 | _a1432-1041 | ||
| 024 | 7 |
_a10.1007/s00228-015-1823-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFulda, Simone | |
| 245 | 0 | 0 |
_aSafety and tolerability of TRAIL receptor agonists in cancer treatment. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cMay 2015 |
||
| 300 |
_a525-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aTNF-Related Apoptosis-Inducing Ligand _xagonists |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 71 _gno. 5 _gp. 525-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00228-015-1823-1 _zAvailable from publisher's website |
| 999 |
_c24644894 _d24644894 |
||